Close

Peptide SQY

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The recognition by T-cell antigen receptors (TCR) of antigenic peptides (p) bound to major histocompatibility complex (MHC)-encoded molecules is the basis of adaptive immune responses. During intrathymic differentiation, the genes encoding the variable (V) domain of the TCRα- and β-chains are assembled by site-specific DNA recombination reactions that result in the random recombination of V, diversity (D), and joining (J) gene segments. It has been argued that each clonally distributed TCR needs to cross-react with structurally distinct pMHC ligands. This property, called TCR degeneracy, is thought to permit the recognition by the whole TCR repertoire of a universe of potential antigenic peptides estimated to be much larger than the number of T-cell clones contained in an individual at a given moment. To differentiate in the thymus and, once mature, to achieve maximal sensitivity upon recognition of peptides of foreign origin, T cells also need to recognize, with low affinity, MHC molecules bearing peptides derived from self-proteins. Therefore, binding degeneracy constitutes an important TCR property.
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC0965 Mouse anti-Peptide SQY T cell receptor ((BM3.3)-8), pCDTCR1 BM3.3 Mouse SQYDYNSL H2-Kb Y22F, M23I, E24S, D30N mutant Lentiviral vector   Add to Cart   Datasheet
TCR-YC0966 Mouse anti-Peptide SQY T cell receptor ((BM3.3)-9), pCDTCR1 BM3.3 Mouse SQYVYNSL H2-Kb Y22F, M23I, E24S, D30N mutant Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.